Use of dual anti platelets in ischemic stroke for how many days
Reading File
Searching PubMed
dual antiplatelet therapy ischemic stroke duration
Finding Sources
Reading Article
PMID: 42218849
Reading File
Reading File
I now have comprehensive data from textbooks and the latest 2026 meta-analysis. Here is the full answer:
Dual Antiplatelet Therapy (DAPT) in Ischemic Stroke - Duration
Who Qualifies for DAPT?
DAPT is indicated for:
- Minor ischemic stroke (NIHSS score ≤3) - not treated with IV alteplase
- High-risk TIA (ABCD2 score ≥4)
- Started within 24 hours of symptom onset
Duration: 21 Days (Standard Regimen)
The landmark evidence comes from two large RCTs:
| Trial | Regimen | Key Finding |
|---|---|---|
| CHANCE (China) | Aspirin + clopidogrel × 21 days, then clopidogrel alone to 90 days | Reduced 90-day stroke recurrence (8.2% vs 11.7%) |
| POINT (USA/International) | Aspirin + clopidogrel × 90 days | Reduced major ischemic events but increased bleeding at 90 days |
A pooled analysis of POINT and CHANCE confirmed that the ischemic benefit of DAPT is confined to the first 21 days. Beyond 21 days, the bleeding risk outweighs any additional stroke protection.
- Rosen's Emergency Medicine states: "treatment with dual antiplatelet therapy (aspirin and clopidogrel) started within 24 hours after symptom onset and continued for 21 days is effective in reducing recurrent ischemic stroke for a period of up to 90 days from symptom onset."
Special Case: Intracranial Atherosclerotic Stenosis
For strokes caused by significant intracranial large artery atherosclerosis (>50% stenosis), DAPT with high-dose aspirin + clopidogrel is given for 90 days, as per Fuster and Hurst's The Heart, 15th Ed.
Alternative: Ticagrelor + Aspirin (THALES Trial)
The THALES trial showed ticagrelor + aspirin is also an accepted option for up to 30 days in minor stroke/high-risk TIA, as referenced in Goldman-Cecil Medicine.
After DAPT: Step Down to Single Antiplatelet
After the DAPT course ends, patients are continued on single antiplatelet therapy (clopidogrel 75 mg OR aspirin 75-100 mg) indefinitely for secondary prevention.
2026 Meta-Analysis Update (PMID 42218849)
A fresh 2026 systematic review analyzing week-by-week outcomes from 4 RCTs (27,167 patients) provides important nuance:
- The ischemic benefit of DAPT is most concentrated in week 1 (benefit-to-risk ratio: 12.87)
- By weeks 2-3, the ratio drops sharply (1.68)
- By week 5, aspirin monotherapy was actually associated with lower ischemic event risk than DAPT
- Major bleeding risk from DAPT persists through weeks 1 and 2
This supports exploring shorter, individualized DAPT strategies (potentially as short as 7-10 days) in patients at higher bleeding risk, though the current standard guideline remains 21 days.
Summary Table
| Stroke Type | DAPT Regimen | Duration |
|---|---|---|
| Minor stroke/High-risk TIA (general) | Aspirin 75-100 mg + Clopidogrel 75 mg | 21 days, then single antiplatelet |
| Intracranial atherosclerotic stenosis | High-dose aspirin + Clopidogrel | 90 days, then single antiplatelet |
| Minor stroke/High-risk TIA (alternative) | Ticagrelor 90 mg BD + Aspirin | 30 days, then single antiplatelet |
Long-term DAPT (>90 days) is NOT recommended for secondary stroke prevention due to excess bleeding risk without additional ischemic benefit. - Fuster and Hurst's The Heart, 15th Ed.
Pt is having still having rt hemiparisis and still using dual antiplalet since 8yrs
Finding Sources
Searching PubMed
long-term dual antiplatelet therapy stroke bleeding risk
Finding Sources
Reading File
Reading File
Here is a thorough clinical assessment of this scenario:
Clinical Analysis: 8 Years of DAPT After Ischemic Stroke
The Core Problem: DAPT Is NOT Indicated Here
This patient's right hemiparesis is a residual/chronic deficit from the original stroke - it is a fixed neurological impairment from damaged brain tissue. It is not an ongoing ischemic event requiring continued DAPT. Continuing DAPT for 8 years based on persistent hemiparesis reflects a fundamental clinical misconception.
"Long-term dual antiplatelet therapy is NOT recommended for secondary stroke prevention." - Fuster and Hurst's The Heart, 15th Ed.
The key evidence against long-term DAPT:
| Trial | Finding |
|---|---|
| MATCH trial | Adding aspirin to clopidogrel after ischemic stroke/TIA: NO significant reduction in major vascular events, but significant increase in life-threatening/major bleeding |
| CHARISMA trial | Adding clopidogrel to aspirin did NOT significantly reduce MI, stroke, or cardiovascular death vs. aspirin alone |
| POINT trial (extended) | Benefit of DAPT confined to first 21 days; beyond 90 days - no ischemic benefit, increased bleeding |
Risks This Patient Has Been Exposed to for 8 Years
- GI hemorrhage - most common; silent GI blood loss leading to iron-deficiency anemia
- Intracranial hemorrhage (ICH) - the most feared complication; risk increases with age, hypertension, and duration
- Spontaneous bruising/mucosal bleeding
- Drug fatigue/non-compliance issues if the indication was never re-evaluated
What Should Be Done Now
Step 1: Stop DAPT immediately - switch to single antiplatelet
- Continue either aspirin 75-100 mg/day OR clopidogrel 75 mg/day (clopidogrel is preferred as it has a slight edge over aspirin in secondary stroke prevention - CAPRIE trial)
- Long-term single antiplatelet IS recommended indefinitely for secondary stroke prevention
Step 2: Reassess stroke etiology
- If stroke was cardioembolic (atrial fibrillation, mechanical valve, intracardiac thrombus) - the patient should be on anticoagulation (DOAC or warfarin), NOT antiplatelet at all
- If stroke was from intracranial atherosclerotic stenosis - single antiplatelet + statin is appropriate
Step 3: Check for bleeding complications
- Full blood count (look for iron-deficiency anemia from occult GI bleed)
- Stool occult blood test
- If any symptoms of GI bleed - upper GI endoscopy
Step 4: Evaluate modifiable risk factors
- Blood pressure control (target <140/90 mmHg)
- High-intensity statin therapy (atorvastatin 40-80 mg)
- HbA1c if diabetic
- Lifestyle modification
Step 5: Neurological rehabilitation assessment
- The right hemiparesis after 8 years is likely fixed, but if not already done, formal physiotherapy and occupational therapy assessment is warranted
- Late neuroplasticity and constraint-induced movement therapy can still help even years post-stroke
Summary
| Aspect | Current Status | Correct Management |
|---|---|---|
| DAPT duration | 8 years (wrong) | Max 21-90 days only |
| Indication for DAPT | Residual hemiparesis (incorrect) | No indication for DAPT |
| Correct long-term therapy | - | Single antiplatelet (clopidogrel preferred) |
| Hemiparesis cause | Chronic deficit, not active ischemia | Rehabilitation, not more antiplatelets |
| Risk incurred | 8 years excess bleeding risk | Screen for GI/ICH complications |
The right hemiparesis is a stroke sequela - the neuron is gone. No antiplatelet drug (single or dual) can reverse or improve it. The goal of long-term antiplatelet therapy is preventing a new stroke, and for that, single antiplatelet is as effective as DAPT with far less risk.
This is a shared conversation. Sign in to Orris to start your own chat.